The Coressence pipeline currently has 9 product lines each at a different stage:

Functional Food		Mode of Action	Novel Food Status	Pre-clinical Studies	Clinical Studies	Placed on Market
Evesse® Juice		eNOS dependent vasodilator	Approved 2006	2007	2008	2007
Evesse® Granules		eNOS dependent vasodilator	Approved 2006	2007	2008	2007
Evesse® Fructose		eNOS dependent vasodilator	Approved 2006	2007	2008	2007
Evesse® Red		Natural Food Colour	Not Required	Licensed	2009	2010
Evesse® EPC		eNOS dependent vasodilator	Awaiting Clearance	Licensed	2009	2010
Pharma /OTC	Mode of Action		Pre-clinical	Phase I	Phase II	Phase III
Topical Cremes	Anti-skin cancer / anti-aging		2009	Out-Licensing	Cooperation	Cooperation
Type II Diabetes	Glucose AbsorptionBlocker		2010	Out-Licensing	Cooperation	Cooperation
Equine Health	Glucose Absorption Blocker /Vasodilator		2010	Out-Licensing	Cooperation	Cooperation
Colon Cancer	Angiogenisis Blocker		2010	Out-Licensing	Cooperation	Cooperation

 1) Evesse Juice - Completed pre-clinical trials in 2007, clinical trials 2008 and placed on the market

 2) Evesse Granules - Completed pre-clinical trials in 2007, clinical trials 2008 and placed on the market

 3) Evesse Fructose - Now a stable intermediate for enzyme activated post-processing

 4) Evesse Red - Clinical trials 2009

 5) Evesse EPC - Clinical trials 2009

 6) Co-EPC3 - Early stage candidate for topical cosmetics applications

 7) EPCO3E - Early stage candidate for Type II diabetic glucose absorption blocker

 8) Co-EPCO3E - Early stage Equine candidate

 9) Candidate colon, skin and prostate cancer molecules

Our candidate molecules are:

 1) manufactured to the highest levels of a cGMP (Good Manufacturing Practice) at a site regularly inspected by authorities such as FDA and MHRA

 2) accompanied by a comprehensive pre-clinical animal toxicology package

 3) being used in numerous ongoing human clinical studies, and

 4) Can be tested in human clinical studies with a short lead time